FACULTY DISCLOSURE INFORMATION

Summer Symposium "Cancer Immunotherapy: Successes, Challenges and New Frontiers"
July 21, 2021

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formerly known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

<table>
<thead>
<tr>
<th>NAME</th>
<th>Individual's Role(s) in Activity</th>
<th>Nothing To Disclose</th>
<th>DISCLOSURE &lt;company &amp; role&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Planning Disclosures</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jarushka Naidoo, MD</td>
<td>Co-Chair</td>
<td>Honoraria: Consulting/AD Board: Bristol Myers Squibb, Merck, AstraZeneca, Takeda, Pfizer, Roche/Genentech. Research funding: PI: Merck, AstraZeneca</td>
<td></td>
</tr>
<tr>
<td>Dmitriy Zamarin, MD PhD</td>
<td>Co-Chair</td>
<td>Consultant: Memgen, Targovax, Roche, Xencor, Synlogic. Investigator: AstraZeneca, Genentech, Plexxikon</td>
<td></td>
</tr>
<tr>
<td><strong>Speaker Disclosures</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stephanie Gaillard, MD PhD</td>
<td>Speaker</td>
<td>Ad Board: Arcus Research Grant: AstraZeneca, Iovance, Tesaro/GSK, Genentech</td>
<td></td>
</tr>
<tr>
<td>Jose Conejo-Garcia, MD PhD</td>
<td>Speaker</td>
<td>Consultant: Leidos Stock: Compass Therapeutics, Alloy Therapeutics Sponsored Research: Anixa Biosciences</td>
<td></td>
</tr>
<tr>
<td>Amir Jazaeri, MD</td>
<td>Speaker</td>
<td>Clinical trial support: Iovance, AstraZeneca, BMS, Eli Lilly, Aravive, Merck  SAB-Stock: AvengeBio  SAB-renumeration Nuprobe</td>
<td></td>
</tr>
<tr>
<td>Jarushka Naidoo, MD</td>
<td>Speaker</td>
<td>Honoraria: Consulting/AD Board: Bristol Myers Squibb, Merck, AstraZeneca, Takeda, Pfizer, Roche/Genentech. Research funding: PI: Merck, AstraZeneca</td>
<td></td>
</tr>
<tr>
<td>Roisin O’Cearbhaill, MD</td>
<td>Speaker</td>
<td>Advisor: Seattle Genetics, Carina Biotechnology Steering Committee Member: Moonstone Tesaro/GSK Clinical Research: Bayer, Celgene, Juno Tesaro/GSK Ludwig</td>
<td></td>
</tr>
<tr>
<td>Dan Powell, PhD</td>
<td>Speaker</td>
<td>Consultant/research: Iovance, Tmunity, AstraZeneca, Eli Lilly,</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Title</td>
<td>Disclosures</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Yu Shyr, PhD</td>
<td>Speaker</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kellie Smith, PhD</td>
<td>Speaker</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oladapo Yeku, MD PhD</td>
<td>Speaker</td>
<td>Consultant: Senti Biosciences  Ad Board: Imvax Inc.  Celldex Therapeutics</td>
<td></td>
</tr>
<tr>
<td>Dmitriy Zamarin, MD PhD</td>
<td>Mod/Speaker</td>
<td>Consultant: Memgen, Targovax, Roche, Xencor, Synlogic. Investigator: AstraZeneca, Genentech, Plexxikon</td>
<td></td>
</tr>
</tbody>
</table>
Accreditation Statement

The GOG Foundation, Inc. is accredited by the ACCME to provide Continuing Medical Education for physicians.

**AMA PRA Category 1 Credits™**

The GOG Foundation, Inc. designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The GOG Foundation Inc. Continuing Medical Education (CME) Program Mission Statement

The purpose of The GOG Foundation, Inc. CME program is to provide and promote an infrastructure dedicated to enhancing the knowledge base of meeting participants and guests centered on the development, execution, analysis and application of GOG-supported clinical trials. To that end, the CME Program engages in these discussions member researchers and invited clinicians committed to reducing the risk and improving outcomes for women at risk for or afflicted with a gynecologic malignancy.

How to Claim CME/CEU Credit

- Access the NRG Meeting Attendee Hub and attend your sessions
  - NRG Meeting/CME: After you attend your sessions, click the button for the Overall Evaluation located on the home page of the Attendee Hub. Once selected, you can complete and submit your Overall Evaluation*.
  - Summer Symposium/CME: Select evaluation and complete immediately following the session. *
  - PSC/CEU: After you attend your sessions, select and complete evaluation then submit.*

- *Certificates: After you submit your evaluations, you should receive an email with instructions to download, save and print your certificate. (Certificates will be sent to the email you used to register.)

For CME questions, please contact cmeinfo@gog.org

Disclosure Information

In compliance with ACCME regulations, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation. Please see the complete disclosure list included with this program.
Summer Symposium
“Cancer Immunotherapy: Successes, Challenges and New Frontiers”
Weds, July 21, 2021 – 1 pm to 5 pm -Eastern Time

NRG Oncology Summer 2021 Virtual Meeting

Program Co-Chairs: Dmitriy Zamarin, MD, PhD and Jarushka Naidoo, MD

PROGRAM DESCRIPTION:

The Summer 2021 GOG Foundation, Inc. Educational Symposium is titled “Cancer Immunotherapy: Successes, Challenges and New Frontiers” with noted Oncologists and Scientists serving as speakers and moderators. The targeted audiences are members and non-members of the NRG research teams to include: Gynecologic Oncologists, Medical Oncologists, Radiation Oncologists, Pathologists, Patient Advocates and others engaged in oncology research and/or clinical practice; Oncology Nurses, Nurse-practitioners, and other interested Allied Health professionals.

The speakers will focus their presentations on the current state-of-the-art developments in the field of cancer immunology and immunotherapy, their application to therapy of gynecologic cancers, and practical considerations for therapy administration and future trials, including immunotherapy-related toxicities, mechanisms of resistance, biomarkers, and clinical trial design.

LEARNING OBJECTIVES:

Following this activity, participants will be better able to:

▪ Implement approved immunotherapies to gynecologic cancer patients on the basis of tumor pathologic and/or molecular characteristics.

▪ Identify immunotherapy-related toxicities and apply appropriate algorithms for toxicity management.

▪ Distinguish different immunotherapy approaches and their potential applicability to their patients.

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 pm</td>
<td>Welcome/Opening Remarks</td>
<td>Dmitriy Zamarin, MD PhD</td>
</tr>
<tr>
<td>1:10 pm</td>
<td>Session 1 -Introduction: Basic Concepts in Tumor Immunology and immunotherapy</td>
<td>Moderator: Dmitriy Zamarin, MD PhD</td>
</tr>
<tr>
<td>1:10 - 1:30 pm</td>
<td>Introduction to Tumor Immunology and Adaptive Immunity, T cell exhaustion, Tumor Microenvironment</td>
<td>Kellie N. Smith, PhD</td>
</tr>
<tr>
<td>1:30 – 1:50 pm</td>
<td>Cancer Vaccines and Immune Checkpoint Blockade</td>
<td>Roisin O’Cearbhaill, MD</td>
</tr>
<tr>
<td>1:50 – 2:10 pm</td>
<td>Adoptive T Cell Therapy</td>
<td>Daniel J. Powell, Jr., PhD</td>
</tr>
</tbody>
</table>
### Session 2 - State of Immunotherapy in Gynecologic Cancers

**Moderator:** Dmitriy Zamarin, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:20 pm - 2:40 pm</td>
<td>Cervical Cancer</td>
<td>Amir Jazaeri, MD</td>
</tr>
<tr>
<td>2:40 pm - 3:00 pm</td>
<td>Endometrial Cancer</td>
<td>Stephanie Gaillard, MD, PhD</td>
</tr>
<tr>
<td>3:00 pm - 3:20 pm</td>
<td>Ovarian Cancer</td>
<td>Oladapo Yeku, MD, PhD</td>
</tr>
</tbody>
</table>

### Session 3 - Therapeutic Challenges and Biomarkers

**Moderator:** Jarushka Naidoo, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 pm - 3:50 pm</td>
<td>Mechanisms of Intrinsic and Acquired Resistance to Immunotherapy</td>
<td>Jose Conejo-Garcia, MD, PhD</td>
</tr>
<tr>
<td>3:50 pm - 4:10 pm</td>
<td>Immune Related Adverse Events</td>
<td>Jarushka Naidoo, MB BCH, MHS</td>
</tr>
<tr>
<td>4:10 pm - 4:30 pm</td>
<td>Immunotherapy Biomarkers</td>
<td>Dmitriy Zamarin, MD, PhD</td>
</tr>
<tr>
<td>4:30 pm - 4:50 pm</td>
<td>Immunotherapy Clinical Trials: Design and Endpoints</td>
<td>Yu Shyr, PhD</td>
</tr>
<tr>
<td>4:50 pm - 5:00 pm</td>
<td>Closing Remarks</td>
<td>Jarushka Naidoo, MB, BCH MHS</td>
</tr>
</tbody>
</table>
Faculty Members

Program Chairs/Moderators

Jarushka Naidoo, MB, BCH MHS  
Consultant Medical Oncologist, Beaumont Hospital  
RCSI University of Health Sciences  
Adjunct Assistant Professor of Oncology  
Johns Hopkins University

Dmitriy Zamarin MD, PhD  
Translational Research Director  
Gynecologic Medical Oncology  
Memorial Sloan Kettering Cancer Center

Speakers

Jose Conejo-Garcia, MD, PhD  
Chair, Department of Immunology  
Co-Leader, Immuno-Oncology Program  
Senior member, Departments of Gynecologic Oncology and Malignant Hematology  
Moffitt Cancer Center  
Professor, Department of Oncological Sciences  
University of South Florida

Stéphanie Gaillard, MD, PhD  
Director, Gyn Cancer Trials  
Assistant Professor, Oncology  
Assistant Professor, Gynecology & Obstetrics  
Johns Hopkins School of Medicine

Amir A. Jazaeri, MD  
Director of Gynecologic Cancer Immunotherapy Program  
University of Texas  
MD Anderson Cancer Center

Roisin O’Cearbhaill, MD  
Associate Attending  
Research Director, Gynecologic Medical Oncology  
Clinical Director, Solid Tumor Malignancies Cellular Therapy  
Memorial Sloan Kettering Cancer Center

Daniel J. Powell Jr., PhD  
Associate Professor, Department of Pathology and Laboratory Medicine  
Perelman School of Medicine  
University of Pennsylvania

Yu Shyr, PhD  
Harold L. Moses Chair in Cancer Research  
Chair, Department of Biostatistics  
Dir, Vanderbilt Center for Quantitative Sciences  
Dir, Vanderbilt Technologies for Advanced Genomics Analysis and Research Design  
Professor of Biostatistics, Biomedical Informatics, and Health Policy  
Vanderbilt University Medical Center

Kellie N. Smith, PhD  
Assistant Professor of Oncology  
Director, FEST and TCR Immunogenomics Core Facility  
Johns Hopkins Bloomberg Kimmel Institute for Cancer Immunotherapy

Oladapo Yeku, MD, PhD  
Gynecologic Medical Oncology Program  
Clinical Assistant in Medicine  
Massachusetts General Hospital  
Instructor, Harvard Medical School
Jarushka Naidoo, MD is a Consultant Medical Oncologist at Beaumont Hospital/Royal College of Physicians of Ireland; and an Adjunct Assistant Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Center for Cancer Immunotherapy, at Johns Hopkins University, in Baltimore, MD.

Dr. Naidoo graduated with her medical degree (MB BCh BAO) from Trinity College Dublin, and completed both internal medicine training and a medical oncology fellowship through the Royal College of Physicians of Ireland. She then completed an awarded advanced fellowship at Memorial Sloan Kettering Cancer Center (New York), and joined the faculty at Johns Hopkins University in 2015. At Johns Hopkins, she led a portfolio of clinical trials and translational studies focused on immunotherapy for lung cancer and immune-related toxicity. She founded and co-chaired the multidisciplinary Johns Hopkins Immune-related Toxicity Team since 2016. Dr. Naidoo currently leads investigator-initiated trials for patients with lung cancer, specifically for those with stage III non-small lung cancer, and those with CNS metastases. She is a leader in the field of immune-related toxicity, having published the first comprehensive analysis of immune-related pneumonitis (Best of J Clin Oncol 2017), bullous pemphigoid (Best of Cancer Immunol Res 2016), and inflammatory arthritis (Ann Rheum Dis 2016). She is the Chair of the Immunotherapy Subcommittee of the US NRG Clinical Trials Cooperative Group, and develops the ASCO, NCCN and SITC Immune-Related Toxicity Guideline Panels. She is the recipient of several grants and awards including a US NIH KL2 Clinical Scholar Award, and a Lung Cancer Foundation of America/IASLC Young Investigator Award on biomarkers of immunotherapy response and toxicity.

Since her return to Ireland (September 2020), she serves as the national chair for lung cancer committee of Cancer Trials Ireland. Her goal is to develop a lung cancer and immunotherapy research program at Beaumont/RCSI, working with Johns Hopkins and other leading US/European cancer institutes and research groups. She is pleased to take referrals for patients with lung cancers, melanoma/skin cancers, or those potentially suitable for immunotherapy or clinical trials, at Beaumont Hospital Dublin.

Dmitriy Zamarin, MD PhD is a medical oncologist and Translational Research Director in the Gynecologic Medical Oncology Service at the Memorial Sloan Kettering Cancer Center. Dr. Zamarin obtained his MD and PhD degrees from the Mount Sinai School of Medicine in New York. He completed residency in Internal Medicine at the Mount Sinai Hospital in New York and fellowship in Hematology/Oncology at the Memorial Sloan Kettering Cancer Center, where he worked under the mentorship of Dr. James Allison and Dr. Jedd Wolchok, studying the mechanisms of response and resistance to immunomodulatory antibody therapy and oncolytic virus-based therapeutics.

Dr. Zamarin is a principal investigator and a translational chair on several institutional and cooperative group clinical trials exploring novel immunotherapy combinations in gynecologic cancers and other solid tumors. His clinical and laboratory research are focused on characterization of biomarkers in patients undergoing immunotherapy and on development of novel immunotherapeutic strategies using immunomodulatory antibodies and genetically-engineered oncolytic viruses. For his work, Dr. Zamarin has received multiple awards, including Damon Runyon Foundation Fellowship Award, Ovarian Cancer Research Fund Liz Tilberis Early Career Award, and the Ovarian Cancer Academy Grant from the Department of Defense.
Jose Conejo-Garcia, MD, PhD completed his medical degree at the University of Zaragoza, and then a residency in Clinical Chemistry and a PhD in Molecular Medicine at the University of Alcala; all in Spain. He then moved to pursue research training on the biology of pancreatic cancer at the University of Bern, Switzerland, before moving to Germany to lead a project of the discovery and characterization of antimicrobial peptides. In 2001 he joined the ovarian cancer research team of Dr. Coukos at the University of Pennsylvania, where he contributed to report for the first time the role of T cell responses in the outcome of ovarian cancer patients. He then joined the Department of Immunology at Dartmouth College, before moving back to the Penn Campus to lead the Tumor Microenvironment and Metastasis Program at The Wistar Institute. Dr. Conejo-Garcia joined Moffitt in November 2016 as chair of the Department of Immunology and co-leader of the Immuno-Oncology Program.

Dr. Conejo-Garcia’s research program focuses on understanding and targeting mechanisms governing the balance between immunosuppression and protective immunity in the tumor microenvironment, with an emphasis on the role of cancer-driven pathological myelopoiesis.

By combining translational understanding and clinical specimens with mechanistic studies in mouse models, Dr. Conejo-Garcia has contributed to elucidate many of the mechanisms driving protective immunity against gynecologic cancers that have been unveiled in recent years, as demonstrated by >150 of recent articles that total >14,000 citations in Scopus. Those include manuscripts in The New England Journal of Medicine, Science, Nature, Cell, Nature Medicine, Cancer Cell, Immunity and Cancer Discovery, among others. He is the principal investigator of 4 major NCI grants and collaborates with other investigators in other funded research projects. Dr. Conejo-Garcia serves as a reviewer on several editorial boards and multiple NIH study sections, as well as CPRIT. He has been invited to present or chair sessions at many international events in 3 continents.

Stéphanie Gaillard, MD, PhD is Director of Gynecologic Cancer Trials and co-Director of the Developmental Therapeutics and Phase I Clinical Trials Program The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Prior to joining Johns Hopkins, she was a faculty member at Duke University Medical Center. Dr. Gaillard earned her medical degree and doctorate of philosophy in cancer biology from Duke University. She then completed her residency training in internal medicine and fellowship training in medical oncology at The Johns Hopkins School of Medicine. Dr. Gaillard specializes in the treatment of gynecologic malignancies, including ovarian, endometrial, and cervical cancers. Her work focuses on developing clinical trials that aim to improve outcomes using promising new biologic, targeted, and immune therapies in addition to standard treatment regimens. Her translational research program focuses on understanding mechanisms of resistance to therapy and the immune environment associated with gynecologic cancers. Dr. Gaillard has been honored with several awards, including the Liz Tilberis Early Career Award from the Ovarian Cancer Research Fund and a Young Investigator Award from the Conquer Cancer Foundation. She was a scholar for the NIH Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) and is a recipient of the Gynecologic Oncology Group (GOG) Foundation Scholar Investigator Award. Dr. Gaillard serves as Co-Chair of the NRG Oncology Phase I subcommittee and as the SPORE representative to the NCI Gynecologic Cancer Steering Committee. She is the primary author or co-author of numerous publications and book chapters and has presented her research both domestically and abroad.
Amir A Jazaeri, MD is a Professor and the Vice Chair for Clinical Research in the Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center. As the Director for the Gynecologic Cancer Immunotherapy Program, he has helped establish a broad base immune-oncology program for gynecologic cancers that include adoptive cell therapies, immune-modulatory therapies, and translational immunobiology. His other areas of research interest include innovative clinical trial designs and identification of novel biomarkers and immunotherapy targets for gynecologic cancers.

Roisin O’Cearbhaill, MB BCh BAO, MRCPI, MRCPUK, is the Clinical Director of the Solid Tumor Program, Cellular Therapeutics Center and Research Director of the Gynecologic Medical Oncology Service at Memorial Sloan Kettering Cancer Center, with a joint faculty appointment at Weill Cornell Medical College. She is the Director, Patient and Family Centered Care Grant initiative and the Vice-Chair, Investigational New Drug/Device committee at MSKCC. Her research focuses on the development of novel targeted and cellular and immune-based approaches to improve outcomes for patients with gynecologic cancers. She serves as Chair, Developmental Therapeutics, NRG Oncology and is on the Solid Tumor Task force for the Center for International Blood and Bone Marrow Transplant Research.

Amir A. Jazaeri, MD
Director of Gynecologic Cancer Immunotherapy Program
University of Texas
MD Anderson Cancer Center

Roisin O’Cearbhaill, MD
Associate Attending,
Research Director, Gynecologic Medical Oncology
Clinical Director, Solid Tumor Malignancies, Cellular Therapy
Memorial Sloan Kettering Cancer Center
Daniel J. Powell, PhD is an Associate Professor in the Department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania (PENN). He is an expert in cancer immunobiology and translational immunotherapy and is recognized for his studies of the role and mechanism of T cell response in the control of cancer, and the application of adoptive lymphocyte immunotherapy, immunomodulation and cancer vaccination in various cancer types. Dr. Powell is the Scientific Director of Immunotherapy for the Division of Gynecologic Oncology at PENN, and the Director of Education for the Parker Center for Cellular Immunotherapy at PENN. Dr. Powell has a strong record of achievement in translational immunotherapy of cancer and serves on various Advisory Boards. He holds multiple patents in the area of T cell therapy, with an emphasis on CAR T cell and tumor infiltrating lymphocyte therapy. Dr. Powell has served as the Deputy Director of PENN’s Cell and Vaccine Production Facility within the Abramson Cancer Center and director of the Tumor BioTrust Collection, a viable tumor bank in support of research efforts and pilot immunotherapy trials. Dr. Powell is a standing member of the NIH Cancer Immunopathology and Immunotherapy (CII) Study Section. His research excellence has been recognized by multiple awards including the American Society of Gene & Cell Therapy’s Outstanding New Investigator Award, PENN’s Emerging Inventor of the Year and the NIH’s Exceptional Performance Award.

Yu Shyr, PhD received his Ph.D. in biostatistics from the University of Michigan (Ann Arbor) in 1994 and subsequently joined the faculty at Vanderbilt University School of Medicine. Dr. Shyr is a Fellow of the American Statistical Association (ASA), an elected fellow of the American Association for the Advancement of Science (AAAS) and a US Food and Drug Administration (FDA) advisory committee voting member. He has published more than 495 peer-reviewed papers in a variety of journals (h-index = 106). Dr. Shyr was the member of the US National Academy of Medicine (IOM) Committee on Policy Issues in the Clinical Development of Biomarkers for Molecularly Targeted Therapies. He has served as a member of the US National Cancer Institute (NCI) Developmental Therapeutics Study Section, Cancer Immunopathology and Immunotherapy Study Section and the Population and Patient-oriented Training Study Section. Dr. Shyr was the co-course director for the AACR/ASCO Methods in Clinical Cancer Research Vail Workshop. He is the Associate Editor for JAMA Oncology, Journal of Thoracic Oncology (JTO), and the Statistical Advisory Board Member for PLoS ONE. In addition, Dr. Shyr is the principle investigator of the NCI U01 grant of Barrett’s esophagus translational research network coordinating center (BETRNetCC). Dr. Shyr’s current research interests focus on developing statistical bioinformatic methods for analyzing next-generation sequencing data based on single cell technology including a series of papers on estimating the sample size requirements for studies conducting sequencing analysis and novel statistical methods for analyzing the single-cell RNA sequencing (scRNA-seq) data.
Kellie N. Smith, PhD, is an Instructor of Oncology in the Bloomberg-Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins School of Medicine.

Dr. Smith, a Baltimore, MD native, completed her doctoral work at the University of Pittsburgh School of Medicine under the direction of Dr. Charles R. Rinaldo with a focus on T cell immunology and immunotherapy. During her fellowship training at Johns Hopkins, she worked under the mentorship of Dr. Drew M. Pardoll identifying the correlates of response to anti-PD-1 immunotherapy in patients with multiple tumor histologies with a specific emphasis on early and advanced stage non-small cell lung cancer. She joined the faculty in early 2016 and has since collaborated with many clinicians within Johns Hopkins and at outside institutions on immunotherapy clinical trials aimed at improving treatment options, preventing disease recurrence, and understanding the predictors of response to treatment in both early and advanced stage disease.

Dr. Smith’s group has developed a novel patent-pending technique to detect and monitor anti-tumor T cells using a simple liquid biopsy approach. This technique, termed MANAFEST (mutation associated neoantigen functional expansion of specific T-cells), is being used in 8 clinical trials and at 5 different research institutions and biotech companies to monitor responses to mutation associated neoantigens, endogenous retroviruses, tumor associated antigens, and viral antigens. This approach has been used to identify neoantigen-specific responses in lung cancer patients with acquired resistance to checkpoint blockade and in colorectal cancer patients with durable clinical benefit to anti-PD-1. More recently, this approach was able to show for the first time that neoantigen-specific T cells are amplified in the periphery following neoadjuvant PD-1 blockade and that these responses may facilitate tumor regression and prevent relapse after surgical resection. Ongoing work includes the bioinformatic analysis of data generated from the MANAFEST assay and interrogation of how chemotherapy-containing checkpoint blockade treatment regimens augment anti-tumor immunity. This work will elucidate prognostic biomarkers of response and resistance to checkpoint blockade and will help stratify patients most likely to benefit from these treatments.

Oladapo Yeku, MD, PhD is an instructor of Medicine at Harvard Medical School and a Clinical Assistant in Medicine at the Massachusetts General Hospital. Dr. Yeku completed his Medical Oncology fellowship training at Memorial Sloan Kettering Cancer Center (MSKCC). During his fellowship training, Dr. Yeku developed broad expertise in managing a broad variety of gynecologic malignancies, including rare tumors such as clear cell and sarcomas. He is a fellow of the American College of Physicians. He has a Ph.D. in molecular and cellular phar-macology and has received postdoctoral training in immunotherapy and adoptive cellular therapy. While at MSKCC, he conducted preclinical, translational, and clinical research on Chimeric Antigen Receptor T-cells for ovarian cancer. His training and expertise include standard systemic treatment options, immunotherapy, targeted therapy, and clinical trials. As a member of The Henri and Belinda Termeer Center for Targeted Therapies and the Cellular Therapeutic Group, Dr. Yeku is actively involved as a Principal Investigator in early phase drug development and adoptive cellular therapy clinical trials. Dr. Yeku is an associate member of the Vincent Center for Reproductive Biology. His laboratory studies the immunosuppressive tumor microenvironment in Gynecologic Cancers and develops immunotherapeutic approaches to overcome these obstacles.
Thank you for registering for this symposium. You can access a PDF version of all FINAL slide presentations presented at this symposium using the following link:

https://www.nrgoncology.org/Resources/Meetings/SymposiumSlides

Thank you for your continued support, have a great meeting!